FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309778908> ?p ?o ?g. }

• W4309778908 abstract "Background Medullary thyroid carcinoma (MTC) is a rare type of thyroid cancer; however, it accounted for 13.4% of the disease-specific mortalities. ALTER01031 (NCT02586350) was a randomised, placebo-controlled phase 2b trial that evaluated the efficacy and safety of anlotinib in locally advanced or metastatic MTC. This post hoc analysis aimed to evaluate the efficacy and safety of anlotinib in older patients and those with bone metastases using ALTER01031. Methods In ALTER01031, anlotinib significantly prolonged the median progression-free survival (PFS) from 11.1 months to 20.7 months compared with placebo in the whole population. Patients who were older (≥ 50 years) or had bone metastases were selected. PFS and overall survival (OS) were estimated and compared between patients receiving anlotinib or placebo in each subgroup. A sub-analysis of tumour response and safety was also performed. Results Patients with older age or bone metastases experienced rapid disease progression as the median PFS was 6.8 months and 7.0 months respectively in the placebo group. Anlotinib significantly improved the median PFS to 17.5 months ( P = 0.002) and 20.7 months ( P = 0.029) with hazard ratio (HR) of 0.31 (95% CI, 0.15–0.68) and 0.44 (95% CI, 0.20–0.94) compared with placebo. Significant benefit in OS was observed in patients with older age after a longer follow-up (HR = 0.47 [95% CI, 0.22–0.99], P = 0.041). The safety profile of these subgroups was similar to that of the entire population. Conclusion This sub-analysis demonstrated significant survival benefits and favourable safety of anlotinib in patients with MTC who had old age or bone metastases, supporting the feasibility of anlotinib in these patients." @default.
• W4309778908 created "2022-11-29" @default.
• W4309778908 creator A5003118713 @default.
• W4309778908 creator A5005066823 @default.
• W4309778908 creator A5010479652 @default.
• W4309778908 creator A5027051284 @default.
• W4309778908 creator A5028631107 @default.
• W4309778908 creator A5031767581 @default.
• W4309778908 creator A5036948980 @default.
• W4309778908 creator A5038677051 @default.
• W4309778908 creator A5042241049 @default.
• W4309778908 creator A5044301848 @default.
• W4309778908 creator A5046000864 @default.
• W4309778908 creator A5047233741 @default.
• W4309778908 creator A5048095374 @default.
• W4309778908 creator A5049832889 @default.
• W4309778908 creator A5052607264 @default.
• W4309778908 creator A5061543595 @default.
• W4309778908 creator A5064080819 @default.
• W4309778908 creator A5065220600 @default.
• W4309778908 creator A5072341364 @default.
• W4309778908 creator A5076582862 @default.
• W4309778908 creator A5088323967 @default.
• W4309778908 date "2022-11-22" @default.
• W4309778908 modified "2023-10-14" @default.
• W4309778908 title "Anlotinib in patients with medullary thyroid carcinoma with negative prognostic factors: A sub-analysis based on the ALTER01031 study" @default.
• W4309778908 cites W2088845284 @default.
• W4309778908 cites W2119501407 @default.
• W4309778908 cites W2122956665 @default.
• W4309778908 cites W2139257964 @default.
• W4309778908 cites W2159234812 @default.
• W4309778908 cites W2237254160 @default.
• W4309778908 cites W2327593094 @default.
• W4309778908 cites W2522497256 @default.
• W4309778908 cites W2603577764 @default.
• W4309778908 cites W2605021316 @default.
• W4309778908 cites W2885503610 @default.
• W4309778908 cites W2889570909 @default.
• W4309778908 cites W2923519145 @default.
• W4309778908 cites W2954224766 @default.
• W4309778908 cites W3023448464 @default.
• W4309778908 cites W3080978633 @default.
• W4309778908 cites W3088191743 @default.
• W4309778908 cites W3088963933 @default.
• W4309778908 cites W3167931732 @default.
• W4309778908 cites W3196453900 @default.
• W4309778908 cites W3007972348 @default.
• W4309778908 doi "https://doi.org/10.3389/fonc.2022.852032" @default.
• W4309778908 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36483043" @default.
• W4309778908 hasPublicationYear "2022" @default.
• W4309778908 type Work @default.
• W4309778908 citedByCount "1" @default.
• W4309778908 countsByYear W43097789082023 @default.
• W4309778908 crossrefType "journal-article" @default.
• W4309778908 hasAuthorship W4309778908A5003118713 @default.
• W4309778908 hasAuthorship W4309778908A5005066823 @default.
• W4309778908 hasAuthorship W4309778908A5010479652 @default.
• W4309778908 hasAuthorship W4309778908A5027051284 @default.
• W4309778908 hasAuthorship W4309778908A5028631107 @default.
• W4309778908 hasAuthorship W4309778908A5031767581 @default.
• W4309778908 hasAuthorship W4309778908A5036948980 @default.
• W4309778908 hasAuthorship W4309778908A5038677051 @default.
• W4309778908 hasAuthorship W4309778908A5042241049 @default.
• W4309778908 hasAuthorship W4309778908A5044301848 @default.
• W4309778908 hasAuthorship W4309778908A5046000864 @default.
• W4309778908 hasAuthorship W4309778908A5047233741 @default.
• W4309778908 hasAuthorship W4309778908A5048095374 @default.
• W4309778908 hasAuthorship W4309778908A5049832889 @default.
• W4309778908 hasAuthorship W4309778908A5052607264 @default.
• W4309778908 hasAuthorship W4309778908A5061543595 @default.
• W4309778908 hasAuthorship W4309778908A5064080819 @default.
• W4309778908 hasAuthorship W4309778908A5065220600 @default.
• W4309778908 hasAuthorship W4309778908A5072341364 @default.
• W4309778908 hasAuthorship W4309778908A5076582862 @default.
• W4309778908 hasAuthorship W4309778908A5088323967 @default.
• W4309778908 hasBestOaLocation W43097789081 @default.
• W4309778908 hasConcept C126322002 @default.
• W4309778908 hasConcept C141071460 @default.
• W4309778908 hasConcept C142724271 @default.
• W4309778908 hasConcept C143998085 @default.
• W4309778908 hasConcept C187960798 @default.
• W4309778908 hasConcept C195121873 @default.
• W4309778908 hasConcept C204787440 @default.
• W4309778908 hasConcept C207103383 @default.
• W4309778908 hasConcept C27081682 @default.
• W4309778908 hasConcept C2780120053 @default.
• W4309778908 hasConcept C2908647359 @default.
• W4309778908 hasConcept C2993294228 @default.
• W4309778908 hasConcept C44249647 @default.
• W4309778908 hasConcept C526584372 @default.
• W4309778908 hasConcept C67761136 @default.
• W4309778908 hasConcept C71924100 @default.
• W4309778908 hasConcept C90924648 @default.
• W4309778908 hasConcept C99454951 @default.
• W4309778908 hasConceptScore W4309778908C126322002 @default.
• W4309778908 hasConceptScore W4309778908C141071460 @default.
• W4309778908 hasConceptScore W4309778908C142724271 @default.
• W4309778908 hasConceptScore W4309778908C143998085 @default.
• W4309778908 hasConceptScore W4309778908C187960798 @default.
• W4309778908 hasConceptScore W4309778908C195121873 @default.

• next